The Palo Alto, Calif.-based company said the acquisition will be beneficial to its portfolio of patient treatment plan QA and machine QA technologies, and that integration of the Mobius’ technologies will enable advanced QA processes to be “seamlessly combined into treatment workflows.”
Mobius’ QA software is currently in use at over 1,000 sites globally, and includes the Mobius3D dose verification and IMRT/VMAT treatment delivery system, the company said.
“Varian has a long history of providing high-quality QA for its products and the treatments they deliver. Varian places high value on the market-leading Mobius QA products, including Mobius3D and DoseLab, and is dedicated to expanding their global reach. The two companies have similar cultures with deep commitments to enabling quality cancer care for patients around the globe,” Varian oncology systems biz prez Kolleen Kennedy said in a press release.